Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 13/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437490 | 0.87 | FABP4 (0.46) | CYP2C9FABP4BRAFCYP3A4CYP2C19 | |
| SCHEMBL913334 | 0.82 | BRAF (0.41) | CYP2C9BRAFCYP3A4CYP2C19 | |
| SCHEMBL20408709 | 0.82 | CYP2C9 (0.57) | CYP2C9FABP4BRAFCYP3A4CYP2C19 | |
| SCHEMBL23458102 | 0.80 | ALDH1A1 (0.42) | FABP4CYP2C19 | |
| SCHEMBL29721191 | 0.80 | ALDH1A1 (0.42) | FABP4CYP2C19 | |
| SCHEMBL3526302 | 0.79 | KDM4E (0.47) | CYP2C9FABP4BRAF | |
| SCHEMBL1868892 | 0.79 | CYP3A4 (0.59) | CYP2C9BRAFCYP3A4CYP2C19 | |
| SCHEMBL1490998 | 0.78 | BRAF (0.54) | CYP2C9FABP4BRAF | |
| SCHEMBL914366 | 0.77 | BRAF (0.40) | CYP2C9FABP4BRAFCYP3A4CYP2C19 | |
| SCHEMBL20408784 | 0.77 | BRAF (0.54) | CYP2C9BRAFCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470541-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025947-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CYP2C9 2807/4885FABP4 3272/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.